News

Inhibiting USP13 Enzyme Can Help Destroy Toxic Alpha-Synuclein Clumps, Mouse Study Finds

Inhibiting an enzyme called USP13 may represent an attractive therapeutic target for Parkinson’s and other neurodegenerative diseases, preclinical data suggests. These findings also could hold important implications for a therapy currently being developed to treat Parkinson’s disease — nilotinib. The study, “Ubiquitin specific protease-13 independently regulates parkin…

Design, Development of BeatHealth System for Parkinson’s Gait Impairments Described in Study

Researchers have developed a system — a mobile app and two websites — based on musical stimuli to improve gait and reduce freezing episodes in Parkinson’s disease patients, according to a study describing the design process of the new approach. The project, called BeatHealth, involved patients, caregivers, and health professionals…

UNS’ Investigational Vaccine UB-312 Holds Potential to Prevent Parkinson’s, Other Neurological Diseases, Data Show

An investigational vaccine being developed by United Neuroscience (UNS) presented several advantages over traditional vaccines to treat progressive disorders, such as Parkinson’s disease, according to preclinical data. The vaccine, called UB-312, was more selective to prevent toxic aggregates of alpha-synuclein in mouse models of the disease. These latest findings were…